Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Anti-prolactin Receptor Antibody LFA102

Known as: LFA102 
A neutralizing antibody against the prolactin receptor (PRLR) with potential antineoplastic activity. Upon administration, anti-prolactin receptor… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
  • V. Goffin
  • Pharmacology & therapeutics
  • 2017
  • Corpus ID: 43669906
In the era of precision medicine, the identification of new targets is a constant challenge to improve cancer therapy… Expand
2016
2016
Lessons Learned Despite evidence for a role for prolactin signaling in breast and prostate tumorigenesis, a prolactin receptor… Expand
  • figure 2
  • figure 1
2016
2016
In this issue of The Oncologist, Agarwal et al. report negative results from a phase I trial of LFA102. Although “negative” in… Expand
  • table 1
Review
2013
Review
2013
The prolactin (PRL)–prolactin receptor (PRLR) signaling complex has been implicated in the pathology of breast and prostate… Expand
  • figure 1
  • figure 2
2013
2013
Numerous lines of evidence suggest that the polypeptide hormone prolactin (PRL)may contribute to breast and prostate… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2012
2012
Numerous lines of evidence suggest that the polypeptide hormone prolactin (PRL) may contribute to breast and prostate… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2012
Review
2012
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Numerous lines of… Expand
  • table 1
2011
2011
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL The prolactin receptor (PRLR) is a class I cytokine… Expand